Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 0

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 0
---
TABLE OF CONTENTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant☐ Check the appropriate box:

| ☒ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant under § 240.14a-12 |

PLUS THERAPEUTICS, INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ |     | No fee required                                                                                      |
| ☐ |     | Fee paid previously with preliminary materials.                                                      |
| ☐ |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

TABLE OF CONTENTS

2710 Reed Road, Suite 160, Houston, TX 77002 (737) 255-7194 July [•], 2025 To Our Stockholders: In the last year, Plus Therapeutics made significant progress in advancing our therapeutic pipeline. Furthermore, in mid-2024, we acquired CNSide TMa novel cerebrospinal fluid assay platform that enables the detection and management of central nervous system cancers. Our lead investigational radiotherapeutic drug, REYOBIQ TM, is currently being evaluated for use in patients with three types of central nervous system cancers. specifically leptomeningeal metastases (LM), pediatric brain cancer (PBC) and recurrent glioblastoma (rGBM). Earlier in 2025, we completed the ReSPECT-LM safety trial and are now enrolling patients in a dose optimization trial to find a safe and effective dose of REYOBIQ we can then take into a US registrational trial. Also in 2025, the FDA cleared Plus to begin enrolling patients in Phase 1/2a trial for children with brain cancer and we anticipate to begin enrolling soon. Our pediatric trial builds